Skip to main content

Ironwood Pharmaceuticals, Inc. (IRWD)

NASDAQ: IRWD · IEX Real-Time Price · USD
13.00
-0.03 (-0.23%)
After-hours:Oct 22, 2021 6:38 PM EDT
13.03
-0.12 (-0.91%)
At close: Oct 22, 4:00 PM
Market Cap2.12B
Revenue (ttm)413.02M
Net Income (ttm)508.86M
Shares Out161.95M
EPS (ttm)3.13
PE Ratio4.16
Forward PE12.33
Dividendn/a
Ex-Dividend Daten/a
Volume2,014,761
Open13.20
Previous Close13.15
Day's Range12.99 - 13.20
52-Week Range8.78 - 14.27
Beta1.31
AnalystsHold
Price Target14.00 (+7.4%)
Est. Earnings DateNov 4, 2021

About IRWD

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development...

IndustryBiotechnology
IPO DateFeb 3, 2010
CEOMark Mallon
Employees232
Stock ExchangeNASDAQ
Ticker SymbolIRWD
Full Company Profile

Financial Performance

In 2020, IRWD's revenue was $389.52 million, a decrease of -9.08% compared to the previous year's $428.41 million. Earnings were $106.18 million, an increase of 393.73%.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for IRWD stock is "Hold." The 12-month stock price forecast is 14.00, which is an increase of 7.44% from the latest price.

Price Target
$14.00
(7.44% upside)
Analyst Consensus: Hold

News

Ironwood Pharmaceuticals to Host Third Quarter 2021 Investor Update Call

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2021 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursd...

1 day ago - Business Wire

6 High Earnings Yield Picks That You Shouldn't Miss Out On

Reap handsome rewards by investing in high earnings yield stocks including MT, MTH, SIMO, DFIN, IRWD, and COLL.

Other symbols:COLLDFINMTMTHSIMO
3 weeks ago - Zacks Investment Research

3 Cheap Healthcare Stocks to Buy Right Now

The Baby Boomers are getting older, which means investors should consider adding undervalued healthcare stocks to their portfolio. The post 3 Cheap Healthcare Stocks to Buy Right Now appeared first on I...

Other symbols:BMYNUS
1 month ago - InvestorPlace

Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will participate in fireside chats at two upcoming virtual investor conferences in September: 2021 Wells Fargo Healthcare Conferenc...

1 month ago - Business Wire

Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) Label

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for LIN...

1 month ago - Business Wire

5 High Earnings Yield Picks to Reap Handsome Rewards

Invest in top-ranked high earnings yield stocks like DFIN, IRWD, LEN, EAT, SGH to strengthen your portfolio.

Other symbols:DFINEATLENSGH
2 months ago - Zacks Investment Research

Ironwood's (IRWD) Q2 Earnings Beat, 2021 Guidance Raised

Ironwood (IRWD) witnesses strong demand for Linzess in the second quarter. Stock up.

2 months ago - Zacks Investment Research

Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported financial results for second quarter 2021 and raised full year 2021 financial guid...

2 months ago - Business Wire

Why Ironwood (IRWD) Could Beat Earnings Estimates Again

Ironwood (IRWD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

2 months ago - Zacks Investment Research

Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced the appointment of John Minardo as senior vice president, chief legal officer. Mr...

2 months ago - Business Wire

Ironwood Pharmaceuticals (IRWD) Reports Next Week: Wall Street Expects Earnings Growth

Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

4 Pharma/Biotech Stocks Poised to Beat on Earnings in Q2

We take a look at a few pharma/biotech companies, which are poised to beat on earnings in the second quarter.

Other symbols:BHCREGNZTS
2 months ago - Zacks Investment Research

Ironwood (IRWD) Hits 52-Week High, Can the Run Continue?

Ironwood (IRWD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

2 months ago - Zacks Investment Research

Ironwood Pharmaceuticals to Host Second Quarter 2021 Investor Update Call

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its second quarter 2021 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thurs...

3 months ago - Business Wire

7 Stocks That Insiders Are Snapping Up Right Now

Tracking stocks insiders are buying is always helpful. Tips for beating the market tend to come and go quickly, but this one has held up.

Other symbols:ACNBADCASANPFSIRIG
3 months ago - InvestorPlace

Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that The American Journal of Gastroenterology – the official journal of The Ameri...

4 months ago - Business Wire

Ironwood Pharmaceuticals Announces Leadership Updates

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the Board of Directors named Thomas McCourt, who has served as president and...

4 months ago - Business Wire

Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS® (linaclotide) 72 mcg Dosage Strength

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. pr...

4 months ago - Business Wire

More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New S...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, presented new findings at the Digestive Disease Week® (DDW) 2021 virtual meeting from a survey hi...

4 months ago - Business Wire

Ironwood Pharmaceuticals to Present New Linaclotide Data and Unveil Findings From GI Disease Surveys at Digestive Dis...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced that the company and its collaborators will present seven posters – four of which ...

5 months ago - Business Wire

Moving Average Crossover Alert: Ironwood Pharmaceuticals (IRWD)

Ironwood Pharmaceuticals (IRWD) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front

5 months ago - Zacks Investment Research

Ironwood's (IRWD) Q1 Earnings Beat, 2021 Guidance Muted

Ironwood (IRWD) witnesses strong demand for Linzess in the first quarter. However, outlook for 2021 misses market expectations.

5 months ago - Zacks Investment Research

Ironwood Pharmaceuticals (IRWD) Q1 Earnings and Revenues Beat Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of 9.09% and 3.82%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Recap: Ironwood Pharmaceuticals Q1 Earnings

Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were up 500.00% over the past year to $0.24, which beat t...

5 months ago - Benzinga

Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program

5 months ago - Business Wire